A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma
Dear Editor,Liver cancer is one of the most frequent malignancies and the second leading cause of cancer-related mortality worldwide.1,2 In the last decade,our understanding of the genetic landscape of hepatocellular carcinoma (HCC) has improved significantly through whole-exome sequencing studies.However,unlike EFGR mutation in lung cancer and BRAF mutation in melanoma,the most frequent mutations in HCC are currently undruggable.Sorafenib,a small-molecule RAF kinase and VEGF receptor kinase inhibitor,was approved for the treatment of advanced HCC patients.However,it only provides limited survival benefit for HCC patients:2.8 months overall survival benefit in the SHARP trial and 2.3 months overall survival benefit for Asia-Pacific patients.3,4 It is therefore urgent to identify new therapeutic approaches for HCC.
28
grants from the Cancer Genomic Center Netherlands,the Dutch Cancer Society;the National Key Basic Research Program of China973 Program:2015CB553905;the National Natural Science Foundation of China81672933,81421001;Shanghai Jiao Tong University School of MedicineYG2014MS44 and PYXJS16-004;Shanghai Municipal Commission of Health and Family Planning2017YQ064 and 201640007
2018-09-28（万方平台首次上网日期，不代表论文的发表时间）
共3页
690-692
